Last reviewed · How we verify
NCT01016795: SCF980266
A Randomized Study of Peripheral Blood Progenitor Cell Priming Comparing a Combination of r-metHuSCF and Filgrastim or Chemotherapy and Filgrastim on Mobilization and Engraftment in Patients With Relapsed or Refractory Lymphomas
Phase 2 trial testing r-metHuSCF and Filgrastim in Malignant Lymphoma in 32 participants. Terminated before completion.
1 November 2000
Quick facts
| Lead sponsor | Aalborg University Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 January 1999 |
| Primary completion | 1 November 2000 |
| Estimated completion | 1 November 2009 |
| Sites | 8 locations across Denmark, Finland, Norway, Sweden |
Drugs / interventions tested
- r-metHuSCF and Filgrastim — full drug profile →
- r-metHuSCF and Filgrastim — full drug profile →
- Chemotherapy plus Filgrastim — full drug profile →
Conditions studied
- Malignant Lymphoma — all drugs for Malignant Lymphoma →
Sponsor
Aalborg University Hospital
Who can join
Adults 18 to 65, any sex, with Malignant Lymphoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Safety and Toxicity was assessed by morbidity, including unexpected adverse events associated with the priming and the transplantation phases during study, and measured and graded by CTC criteria.
Time frame: From inclusion to 1 months post transplantation
Sponsor's own description
Clinical Hypothesis: It is expected that by removing chemotherapy and adding ancestim to the mobilization scheme in most of the subjects sufficient PBPC will be harvested with a minimum of toxicity and side effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01016795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Lymphoma
Currently open trials in the same condition.
- NCT06475820 — Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Yo · Phase 2, PHASE3 · active not recruiting
- NCT05515029 — Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patie · Phase 3 · active not recruiting
Other Aalborg University Hospital trials
Trials by the same sponsor.
- NCT06960005 — ThyMoves: Screening and Exercise to Improve Muscle, Enhance Quality of Life, and Reduce Fall Risk in Thyroid Disease · NA · enrolling by invitation
- NCT06745544 — Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes · NA · recruiting
- NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
- NCT07165574 — Prevalence of Anticholinergics in Geriatric Patients With Acute Functional Deterioration · not yet recruiting
- NCT07173413 — Assessing the Quality of Telephone Follow-Up After Spine Surgery · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01016795 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aalborg University Hospital
- Last refreshed: 24 June 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01016795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing